DotBio, a Singapore-based biopharmaceutical company advancing antibody therapeutic modalities to bring more effective therapies to patients, closed a USD 5.6m Pre-Series A financing round.
The round was led by Proxima Ventures and Gaorong Capital, joined by Chaperone Investment, Protect Biotech and AIM-HI Accelerator Fund. Haolin Sung, EMBA, a serial biotech entrepreneur and Partner of Proxima Ventures, joined DotBio as a member of the Board. Dr Beilin Le, PhD, an Executive Director of Gaorong Capital’s Healthcare Division, will join DotBio as a Board Observer. Dr Sujuan Ba, PhD, Co-Founder and CEO of AIM-HI Accelerator Fund, will join DotBio as a Strategic Advisor.
The company intends to use the funds to commence pre-clinical studies, including animal efficacy and Chemical, Manufacturing and Controls studies, that will validate its therapeutic candidates ahead of future clinical development, and to scale its proprietary, modular DotBody platform to allow for the screening of thousands of multi-functional antibody prototypes against diverse extracellular and intracellular immune-oncology targets that are suited as next-generation clinical candidates.
Led by Ignacio Asial, Chief Executive Officer, DotBio is an immuno-oncology company developing multi-functional and intracellular antibody therapies. The company takes an innovative therapeutic approach towards the ideal treatment: the rapid prototyping of multi-functional antibodies to identify molecules with synergistic activity combinations, optimal architectures and unique mechanisms of action. DotBio’s approach involves the use of its modular DotBody technology platform, its CoFi and Hot-CoFi stabilization technologies, high-throughput miniaturized assays and data analytics to generate unique therapeutic molecules that target both extracellular and intracellular disease drivers.
FinSMEs
10/08/2023